Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
GH
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth StockStory - Fri May 8, 1:11PM CDT

GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth

GH : 95.70 (+3.73%)
MarketBeat.com
Guardant Health Q1 Earnings Call Highlights MarketBeat - Thu May 7, 9:13PM CDT

Guardant Health (NASDAQ:GH) reported a strong start to 2026, citing accelerating adoption across its oncology, biopharma and data, and screening businesses as the company delivered $302 million in first-quarter...

GH : 95.70 (+3.73%)
GH
Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars StockStory - Thu May 7, 4:19PM CDT

Guardant Health (NASDAQ:GH) Delivers Impressive Q1 CY2026, Stock Soars

GH : 95.70 (+3.73%)
Guardant Health: Q1 Earnings Snapshot AP - Thu May 7, 3:46PM CDT

Guardant Health: Q1 Earnings Snapshot

GH : 95.70 (+3.73%)
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Business Wire - Thu May 7, 3:05PM CDT

First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth...

GH : 95.70 (+3.73%)
Guardant Health's Path to Profitability Gets Its Latest Cross-Examination Thursday Barchart - Wed May 6, 4:14PM CDT

Barchart Research What to Expect from GH Earnings GH Generated May 6, 2026 Current Price $92.25 EPS Estimate $$-0.71 Consensus Rating Strong Buy Average Move 11.54% Guardant Health's Path to Profitability...

GH : 95.70 (+3.73%)
GH
Guardant Health Earnings: What To Look For From GH StockStory - Tue May 5, 10:31PM CDT

Guardant Health Earnings: What To Look For From GH

GH : 95.70 (+3.73%)
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations Business Wire - Mon May 4, 7:05AM CDT

Blood-based test enables identification of patients eligible for targeted treatment with VEPPANU ™ Approval marks Guardant’s third...

GH : 95.70 (+3.73%)
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform Business Wire - Thu Apr 30, 7:05AM CDT

Multi-year global collaboration will leverage Guardant’s tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies

GH : 95.70 (+3.73%)
NUVL : 105.28 (+2.81%)
Guardant Health to Participate in Upcoming Investor Conferences Business Wire - Wed Apr 29, 3:05PM CDT

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities...

GH : 95.70 (+3.73%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply Barchart - Sun May 10, 4:00PM CDT
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.